ArticleBlood advances2022

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.

Ulrich Jaeger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.